Pain, Intractable Clinical Trial
Official title:
Efficacy and Safety of Wound Dressing Containing Silk Fibroin With Bioactive Coating Layer Versus Medicated Paraffin Gauze Dressing in the Treatment of Split-thickness Skin Graft Donor Sites
A split-thickness skin graft (STSG) is used for a large wounds or wounds that cannot be closed by primary and secondary wound closure. Accelerated re-epithelialization rate and minimizing pain and infection are main goals of donor care. Traditionally dressings are inexpensive but adhere to the wound surface and cannot absorb exudates. Thus, we have developed a new biomaterial based on Thai silk for wound dressing application. Silk fibroin and silk sericin were selected to produce wound dressing in this study. The objective of this study is to compare wound dressing containing silk fibroin with bioactive coating layer with standard dressing (medicated paraffin gauze dressing; Bactigras®), with regard to healing time, patients' pain intensity, skin's transepidermal water loss after healing and evidence of infection in the treatment of split-thickness skin graft donor sites. The study design is a randomized, controlled, self paired clinical trial. Patients age 18 to 60 years and undergo STSG at thigh in Department of Surgery, King Chulalongkorn Memorial Hospital will be recruited in the study. The exclusion criteria are donor sites other than thigh area or located at high risk of infection. Patients who are immunocompromised or diabetes mellitus or psychiatric disorders or low serum albumin level (less than 3.0 g/dL) or known allergic to SS or SF or paraffin or chlorhexidine acetate are also excluded. All subjects sign the informed consents after discussion the protocol, benefits and risks. The donor site will be divided into two equal halves, each site will be randomized to receive the tested material or the medicated paraffin gauze dressing. The donor site wounds will be observed daily. The dressings will not be changed, except when they are fully soaked with exudates and easily fell off or any sign of infection. Healing time will be recorded when the dressing separate completely from the donor site, no exudates and no pain when the donor site is exposed to air. The patient's pain level will be evaluated with the visual analogue scale and the donor site wounds will be observed daily for signs of infection. On the day of the wound is recorded for healing time and 1 weeks, 1, 2, 3, 4 and 5 months after that, the skin barrier function (TEWL) of each site will be measured using a Tewameter. Blood sample will be collected from patients pre- and postoperatively (within day 3) for hepatic and renal function analysis.
1. To compare the healing times of the split-thickness skin graft donor site under wound
dressing containing silk fibroin woven fabric with bioactive coating layer and
medicated paraffin gauze dressing.
2. To compare the patients' pain levels of the split-thickness skin graft donor site under
wound dressing containing silk fibroin woven fabric with bioactive coating layer and
medicated paraffin gauze dressing.
3. To compare the chance of infections of the split-thickness skin graft donor site under
wound dressing containing silk fibroin woven fabric with bioactive coating layer and
medicated paraffin gauze dressing.
4. To determine the complications with the use of wound dressing containing silk fibroin
woven fabric with bioactive coating layer.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03887494 -
Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY)
|
N/A | |
Recruiting |
NCT05761392 -
APP-based Precise Management System of Chronic Intractable Pain
|
N/A | |
Suspended |
NCT05067257 -
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Withdrawn |
NCT01951911 -
Effectiveness of Ketamine in Malignant Neuropathic Pain Relief
|
Phase 3 | |
Completed |
NCT04701008 -
Efficacy of Ketamine in Post Anesthesia Recovery Room
|
||
Completed |
NCT03350256 -
BurstDRā¢ micrOdosing stimuLation in De-novo Patients
|
N/A | |
Completed |
NCT04602286 -
How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample)
|
N/A | |
Completed |
NCT04625504 -
Investigating Biological Targets, Markers, and Intervention for Chronic Pain
|
N/A | |
Recruiting |
NCT05398003 -
Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M)
|
N/A | |
Completed |
NCT02886286 -
Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain
|
Phase 4 | |
Completed |
NCT00216684 -
Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics
|
Phase 3 | |
Recruiting |
NCT05775510 -
Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain
|
||
Active, not recruiting |
NCT04727216 -
Intermittent vs. Continuous Dorsal Root Ganglion Stimulation
|
N/A | |
Completed |
NCT01166906 -
Pain Blocking During Drug Administration or Blood Collection With Needles
|
||
Recruiting |
NCT04876469 -
Radiocontrast Media in the Pulsed Radiofrequency Treatment
|
N/A | |
Completed |
NCT05108103 -
Determination of Longus Colli Muscle Thickness by Ultrasonography
|
||
Completed |
NCT04727749 -
Pawsitive Impacts of Therapy Dog Visits
|
N/A | |
Completed |
NCT04096391 -
Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population
|
N/A | |
Terminated |
NCT00122915 -
CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain
|
Phase 3 |